| . | JDM (n = 20) . | HC (n = 21) . | P-value . |
|---|---|---|---|
| Age at enrolment, years | 9.2 (1.0) | 9.8 (0.6) | 0.59 |
| Disease onset age, years | 5.0 | NA | |
| Delay in diagnosis, months | 9.5 (4.3) | NA | |
| Interval between diagnosis to urine collection, years | 1.20 (0.2) | NA | |
| Gender, n | 0.92 | ||
| Female | 14 | 15 | |
| Male | 6 | 6 | |
| Race/Ethnicity, n | 0.01 | ||
| Caucasian | 10 | 18 | |
| Non-Caucasian | 10 | 3 | |
| African-American | 3 | 1 | |
| Hispanic | 3 | 2 | |
| Asian | 1 | 0 | |
| Multi-racial or unknown | 3 | 0 | |
| Myositis-specific autoantibody, n | NA | ||
| Anti-p155/140 (TIF1) | 12 | ||
| Anti-MJ (NXP-2) | 5 | ||
| Anti-MDA5 | 3 | ||
| MD global disease activity, 0–10 cm VAS | 3.8 (0.39) | NA | |
| Medication, n | |||
| Prednisone | 17 | 0 | |
| Average dose mg/kg/day (SEM) | 0.60 (0.1) | ||
| Methotrexate | 12 | 0 | |
| IVIG | 9 | 0 | |
| Ciclosporin | 3 | 0 | |
| Average number of immunosuppressivesa | 2.3 (0.24) | 0 | |
| Urine protein level, mg/dl | 262.0 (34.0) | 214.8 (17.9) | 0.22 |
| . | JDM (n = 20) . | HC (n = 21) . | P-value . |
|---|---|---|---|
| Age at enrolment, years | 9.2 (1.0) | 9.8 (0.6) | 0.59 |
| Disease onset age, years | 5.0 | NA | |
| Delay in diagnosis, months | 9.5 (4.3) | NA | |
| Interval between diagnosis to urine collection, years | 1.20 (0.2) | NA | |
| Gender, n | 0.92 | ||
| Female | 14 | 15 | |
| Male | 6 | 6 | |
| Race/Ethnicity, n | 0.01 | ||
| Caucasian | 10 | 18 | |
| Non-Caucasian | 10 | 3 | |
| African-American | 3 | 1 | |
| Hispanic | 3 | 2 | |
| Asian | 1 | 0 | |
| Multi-racial or unknown | 3 | 0 | |
| Myositis-specific autoantibody, n | NA | ||
| Anti-p155/140 (TIF1) | 12 | ||
| Anti-MJ (NXP-2) | 5 | ||
| Anti-MDA5 | 3 | ||
| MD global disease activity, 0–10 cm VAS | 3.8 (0.39) | NA | |
| Medication, n | |||
| Prednisone | 17 | 0 | |
| Average dose mg/kg/day (SEM) | 0.60 (0.1) | ||
| Methotrexate | 12 | 0 | |
| IVIG | 9 | 0 | |
| Ciclosporin | 3 | 0 | |
| Average number of immunosuppressivesa | 2.3 (0.24) | 0 | |
| Urine protein level, mg/dl | 262.0 (34.0) | 214.8 (17.9) | 0.22 |
Data are shown as mean (SEM), except for gender, race and medication which are shown as N.
Including those listed under medications, as well as tacrolimus (n = 1), infliximab (n = 1), mycophenolate (n = 1).
HC: healthy control; IVIG: immunoglobulin; MD: medical doctor/physician; SEM: standard error of the mean; VAS: visual analogue scale; NA: not applicable.
| . | JDM (n = 20) . | HC (n = 21) . | P-value . |
|---|---|---|---|
| Age at enrolment, years | 9.2 (1.0) | 9.8 (0.6) | 0.59 |
| Disease onset age, years | 5.0 | NA | |
| Delay in diagnosis, months | 9.5 (4.3) | NA | |
| Interval between diagnosis to urine collection, years | 1.20 (0.2) | NA | |
| Gender, n | 0.92 | ||
| Female | 14 | 15 | |
| Male | 6 | 6 | |
| Race/Ethnicity, n | 0.01 | ||
| Caucasian | 10 | 18 | |
| Non-Caucasian | 10 | 3 | |
| African-American | 3 | 1 | |
| Hispanic | 3 | 2 | |
| Asian | 1 | 0 | |
| Multi-racial or unknown | 3 | 0 | |
| Myositis-specific autoantibody, n | NA | ||
| Anti-p155/140 (TIF1) | 12 | ||
| Anti-MJ (NXP-2) | 5 | ||
| Anti-MDA5 | 3 | ||
| MD global disease activity, 0–10 cm VAS | 3.8 (0.39) | NA | |
| Medication, n | |||
| Prednisone | 17 | 0 | |
| Average dose mg/kg/day (SEM) | 0.60 (0.1) | ||
| Methotrexate | 12 | 0 | |
| IVIG | 9 | 0 | |
| Ciclosporin | 3 | 0 | |
| Average number of immunosuppressivesa | 2.3 (0.24) | 0 | |
| Urine protein level, mg/dl | 262.0 (34.0) | 214.8 (17.9) | 0.22 |
| . | JDM (n = 20) . | HC (n = 21) . | P-value . |
|---|---|---|---|
| Age at enrolment, years | 9.2 (1.0) | 9.8 (0.6) | 0.59 |
| Disease onset age, years | 5.0 | NA | |
| Delay in diagnosis, months | 9.5 (4.3) | NA | |
| Interval between diagnosis to urine collection, years | 1.20 (0.2) | NA | |
| Gender, n | 0.92 | ||
| Female | 14 | 15 | |
| Male | 6 | 6 | |
| Race/Ethnicity, n | 0.01 | ||
| Caucasian | 10 | 18 | |
| Non-Caucasian | 10 | 3 | |
| African-American | 3 | 1 | |
| Hispanic | 3 | 2 | |
| Asian | 1 | 0 | |
| Multi-racial or unknown | 3 | 0 | |
| Myositis-specific autoantibody, n | NA | ||
| Anti-p155/140 (TIF1) | 12 | ||
| Anti-MJ (NXP-2) | 5 | ||
| Anti-MDA5 | 3 | ||
| MD global disease activity, 0–10 cm VAS | 3.8 (0.39) | NA | |
| Medication, n | |||
| Prednisone | 17 | 0 | |
| Average dose mg/kg/day (SEM) | 0.60 (0.1) | ||
| Methotrexate | 12 | 0 | |
| IVIG | 9 | 0 | |
| Ciclosporin | 3 | 0 | |
| Average number of immunosuppressivesa | 2.3 (0.24) | 0 | |
| Urine protein level, mg/dl | 262.0 (34.0) | 214.8 (17.9) | 0.22 |
Data are shown as mean (SEM), except for gender, race and medication which are shown as N.
Including those listed under medications, as well as tacrolimus (n = 1), infliximab (n = 1), mycophenolate (n = 1).
HC: healthy control; IVIG: immunoglobulin; MD: medical doctor/physician; SEM: standard error of the mean; VAS: visual analogue scale; NA: not applicable.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
